Natco Pharma Brand Guidelines: Hyderabad 1981, a 2012 Compulsory Licence & Oncology Generics

A pharmacist back from the United States and a plant south of Hyderabad.

Natco Pharma was founded in 1981 by V. C. Nannapaneni, English Wikipedia says. The company’s own timeline dates its start to the incorporation that year of the NATCO Pharma Division at Kothur, in the Mahabubnagar district of what is now Telangana, and counts 1984 as its first full year of operation. Natco’s management page says Nannapaneni, who remains chairman and managing director, studied pharmacy at Andhra University in Visakhapatnam and worked for pharmaceutical companies in the United States for more than a decade before returning to India.

The company grew by adding plants and divisions around Hyderabad. Its timeline, which English Wikipedia follows, lists a parenterals plant for injectable products at Nagarjuna Sagar in 1986 and a chemical division at Mekaguda in 1993, where it makes active pharmaceutical ingredients. In 1995, the company says, it merged three group companies into the parent and set up the NATCO Trust, its charitable arm; in 1997 it opened the NATCO Research Centre at Sanathnagar in Hyderabad.

Natco describes its business today in three parts: finished dosage formulations, active pharmaceutical ingredients and, since 2019, a Crop Health Sciences division making agrochemical products. English Wikipedia describes the company as a producer of branded oncology medicines and of specialty drugs in cardiology and diabetology. The company says its API work concentrates on molecules with difficult chemistry and long synthesis routes, with a particular focus on cancer medicines.

The name is usually set in capitals on the company’s own pages, as NATCO; this guide uses the standard spelling Natco Pharma throughout.

Cancer generics and a landmark patent order.

Oncology became Natco’s calling card in 2003, when, the company says, it launched an oncology division with VEENAT, its generic imatinib mesylate for a form of leukaemia. Further plants followed: a finished-dosage facility at Dehradun in Uttarakhand in 2006 and NATCO Organics at Chennai in 2010, which the company says was built for cytotoxic APIs and biotechnology products.

A patent decision put Natco in the news in March 2012. On 9 March 2012 India’s Controller of Patents granted Natco a compulsory licence on Bayer’s Indian patent for Nexavar, the brand name of the cancer drug sorafenib, allowing Natco to make and sell a generic version. The intellectual-property firm Khurana & Khurana, writing on 31 March 2012, called it India’s first compulsory licence, granted under section 84 of the Patents Act, and reported that the order required Natco to pay Bayer a royalty of 6% of sales and to supply the drug free of charge to at least 600 patients a year. Bayer appealed. According to the law firm Nishith Desai Associates, the Intellectual Property Appellate Board dismissed the appeal in March 2013 while raising the royalty to 7%, and the Bombay High Court later upheld the Board’s order.

Natco’s timeline also traces a steady move into the United States. It says it filed its first abbreviated new drug application there in 2007 and its first Paragraph IV patent challenge in 2008, and that it later launched, among others, oseltamivir capsules in 2016, glatiramer acetate injection in 2017 and, in 2022, what it calls the first generic version of Revlimid, lenalidomide capsules. English Wikipedia adds that several US launches were made with marketing partners, including Mylan for glatiramer acetate. In India, Natco says it launched generic sofosbuvir for hepatitis C in 2015 and started cardiology and diabetology divisions in 2017.

A newer formulation plant at Visakhapatnam began commercial production in 2019 and received US FDA approval in 2020, according to the company. In 2023 it set up subsidiaries in Indonesia, the United Kingdom and Colombia, adding to earlier ones in Brazil, Singapore, Canada and Australia.

How Indian drug makers present themselves.

India’s drug makers are spread across several states, and some regions have become clusters. English Wikipedia’s article on the pharmaceutical industry in Gujarat calls Ahmedabad and Vadodara the state’s pharmaceutical hubs and records that the state government declared Gujarat a “pharma hub” in 2000; Torrent Pharma’s plants at Chhatral and Dahej are in the same state. Glenmark’s August 2026 factsheet lists formulation plants in Goa, Sikkim, Madhya Pradesh, Himachal Pradesh and Maharashtra, as well as in Argentina, the United States and the Czech Republic.

Many of the companies in this guide began as family firms and still carry their founders’ stories. Glenmark’s name, English Wikipedia says, was made from the names of its founder’s two sons; Torrent Pharma started in 1959 as Trinity Laboratories and belongs to a group that also runs power and gas businesses. Where a company’s history rests only on its own website, this guide says so.

The industry has its own meeting places. CPHI India, the Informa trade fair that bills itself as “the heart of South Asia’s pharma,” runs from 23 to 26 November 2026 at the IICC in Delhi, alongside the PMEC India machinery show at Greater Noida, according to its website. DCAT Week, which calls itself “the premier event for the global bio/pharmaceutical business ecosystem,” is next held in New York City from 15 to 18 March 2027.

This guide looks at how each company presents itself — in plant photographs, laboratory imagery, packs, founder portraits and corporate colours — and sets out what can be checked about each one: who founded it, who owns it and where it says its medicines are made, marking clearly what rests only on the company’s own word.

From Telangana plants to a South African partner.

Natco’s recent expansion abroad runs through Adcock Ingram, the South African pharmaceutical group. Indian Pharma Post reported on 15 July 2026 that Natco first took a 35.75% stake through Adcock Ingram’s delisting process, after a firm intention offer announced in July 2025, shareholder approval in October 2025 and completion in November 2025; English Wikipedia notes that the transaction took Adcock Ingram off the Johannesburg Stock Exchange. In July 2026 Natco completed the purchase of a further 13.25% through its South African subsidiary, taking its holding to 49%, the same report said.

Its plants have also drawn regulatory scrutiny. Indian Pharma Post reported on 10 April 2024 that Natco had received a US FDA warning letter dated 8 April 2024 relating to a good-manufacturing-practice inspection in October 2023 at its Kothur pharma division, the company’s original site. Natco said then that it did not expect the letter to disrupt supplies from the plant, that it could delay pending approvals from that site, and that it would respond within the required timelines.

The company’s recent timeline also lists minority investments in biotechnology ventures, among them eGenesis in 2024 and Cellogen Therapeutics, and launches in India in 2026 including risdiplam, which it calls the first generic in India, and semaglutide vials. The founding family remains in charge: the management page lists V. C. Nannapaneni as chairman and managing director and Rajeev Nannapaneni as vice-chairman and chief executive.

For a design guide, Natco Pharma shows a specialist identity built on a narrow promise — hard-to-make medicines — rather than a consumer brand. Compare Dr. Reddy’s and Aurobindo, two other Hyderabad drug makers. For this guide we use a deep blue, a teal and a warm white with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Natco Pharma’s identity on hand — save it to a board in the Made Good inspiration library.